title: Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis.
abstract: Ceftazidime is a broad-spectrum cephalosporin with high-level activity against a variety of Gram-negative pathogens, including Pseudomonas aeruginosa. Improved outcomes are associated with cumulative percentages of a 24-h period that the drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (%TMIC) of >45 to 70% of the dosing interval. Optimal dosing to achieve a 90% probability of target attainment (PTA) in patients receiving high-flux hemodialysis (HFHD) is unknown. We used existing data from six anephric adults receiving hemodialysis to construct a population model with the Pmetrics package for R. From the final model's joint probability density, we simulated the PTA for various ceftazidime dosing regimens, HFHD schedules, and organism MICs. For HFHD every 48 h and 1 g of ceftazidime given posthemodialysis, the PTA exceeds 90% for all isolates with MICs of ≤8 μg/ml, assuming a goal of 70%TMIC. For 72-h dialysis intervals, postdialysis dosing of 1 g is adequate for achievement of the 70%TMIC goal only for organisms with MICs of ≤4 μg/ml, while 2 g is adequate for organisms with MICs of ≤8 μg/ml. A dose of 500 mg once daily, regardless of HFHD schedule, has a 90% PTA for organisms with MICs of ≤16 μg/ml, while 1 g once daily may achieve 100% PTA even for resistant organisms with a MIC of 32 μg/ml. Therefore, to ensure maximal ceftazidime activity, once-daily dosing of 500 mg to 1 g ceftazidime in patients receiving HFHD may be preferable for critically ill patients when MIC data are unavailable and for more resistant organisms with ceftazidime MICs of 16 to 32 μg/ml.
authors.affiliation: New York-Presbyterian/Weill Cornell Medical Center, New York, New York, USA.
authors.forename: Angela S
authors.initials: AS
authors.lastname: Loo
authors.forename: Michael
authors.initials: M
authors.lastname: Neely
authors.forename: Evan J
authors.initials: EJ
authors.lastname: Anderson
authors.forename: Cybele
authors.initials: C
authors.lastname: Ghossein
authors.forename: Milena M
authors.initials: MM
authors.lastname: McLaughlin
authors.forename: Marc H
authors.initials: MH
authors.lastname: Scheetz
mesh_terms: D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D002442:Ceftazidime / Q000493:pharmacokinetics* / Q000494:pharmacology; D015169:Colony Count, Microbial; D003198:Computer Simulation; D004334:Drug Administration Schedule; D054796:Drug Dosage Calculations; D006801:Humans; D007262:Infusions, Intravenous; D008826:Microbial Sensitivity Tests; D015233:Models, Statistical; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000254:growth & development; D006435:Renal Dialysis / Q000379:methods*; D051436:Renal Insufficiency, Chronic / Q000382:microbiology / Q000628:therapy
chemical_list: D000900:Anti-Bacterial Agents; D002442:Ceftazidime
references.citation: Clin Infect Dis. 2003 Jan 15;36(Suppl 1):S42-50
references.pmid: 12516029
references.citation: Clin Ther. 2010 Apr;32(4):766-79
references.pmid: 20435246
references.citation: Infect Control Hosp Epidemiol. 2002 Dec;23(12):721-4
references.pmid: 12517013
references.citation: Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):89-96
references.pmid: 7587056
references.citation: Clin J Am Soc Nephrol. 2011 Sep;6(9):2247-52
references.pmid: 21737847
references.citation: Antimicrob Agents Chemother. 2010 Mar;54(3):1111-6
references.pmid: 20038614
references.citation: Clin Nephrol. 1985 Sep;24(3):142-6
references.pmid: 3899438
references.citation: J Antimicrob Chemother. 1981 Sep;8 Suppl B:225-6
references.pmid: 19802989
references.citation: Diagn Microbiol Infect Dis. 2011 Mar;69(3):291-306
references.pmid: 21353957
references.citation: Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):351-61
references.pmid: 16863448
references.citation: Diagn Microbiol Infect Dis. 2005 Jul;52(3):265-73
references.pmid: 16105569
references.citation: J Antimicrob Chemother. 1983 Jul;12 Suppl A:241-5
references.pmid: 6352626
references.citation: J Infect Chemother. 2003 Dec;9(4):292-6
references.pmid: 14691648
references.citation: Clin Infect Dis. 2011 Sep;53 Suppl 2:S33-55; quiz S56-8
references.pmid: 21868447
references.citation: Diagn Microbiol Infect Dis. 2009 Dec;65(4):414-26
references.pmid: 19833471
references.citation: Antimicrob Agents Chemother. 2004 Jul;48(7):2464-70
references.pmid: 15215095
references.citation: J Pharmacokinet Pharmacodyn. 2013 Apr;40(2):189-99
references.pmid: 23404393
references.citation: J Antimicrob Chemother. 2013 Apr;68(4):900-6
references.pmid: 23190766
references.citation: Ther Drug Monit. 2012 Aug;34(4):467-76
references.pmid: 22722776
references.citation: Diagn Microbiol Infect Dis. 2000 Feb;36(2):125-9
references.pmid: 10705055
references.citation: Antimicrob Agents Chemother. 1984 May;25(5):638-42
references.pmid: 6375562
references.citation: Mayo Clin Proc. 1999 Feb;74(2):187-95
references.pmid: 10069359
references.citation: Am J Med Sci. 2008 Oct;336(4):297-302
references.pmid: 18854670
references.citation: Diagn Microbiol Infect Dis. 2005 Jul;52(3):173-9
references.pmid: 16105561
references.citation: Ann Pharmacother. 2009 Feb;43(2):220-7
references.pmid: 19193582
references.citation: Eur J Clin Pharmacol. 1986;30(5):597-605
references.pmid: 3530782
references.citation: Semin Dial. 2008 Jan-Feb;21(1):24-8
references.pmid: 18251954
references.citation: Antimicrob Agents Chemother. 2009 Jul;53(7):2974-81
references.pmid: 19380594
references.citation: Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2
references.pmid: 9455502
references.citation: Infect Dis Clin North Am. 2009 Dec;23(4):791-815, vii
references.pmid: 19909885